VivoSeq
Neurology

Migraine

278

Pipeline Programs↗

132

Active Trials↗

90

Companies Involved↗

Migraine is a highly competitive landscape with 278 programs across 90 companies. The most active players are Scilex Pharmaceuticals, Inc., Ultragenyx, Averitas Pharma, Inc.. 67 therapies are approved with 69 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

87/100

Pipeline Velocity

57/100

Mech. Concentration

11/100

Completion Rate

87/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Scilex Pharmaceuticals, Inc.

1 program

Phase 1Ultragenyx logo

Ultragenyx

1 program

Phase 1A

Averitas Pharma, Inc.

1 program

Phase 1COMPASS Pathways logo

COMPASS Pathways

1 program

Phase 1V

Viatris Specialty LLC

3 programs

Phase 1A

Allodynic Therapeutics, Inc

4 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

323 of 333 classified programs — the dominant modality here.

3%ALL OTHERSMonoclonal antibody62%Peptide3<1%Protein / enzyme1<1%

Small molecule leads; the ring shows all 333 classified programs, each share of the total. Modality classified for 96% of 358 pipeline programs.

Analysis

Trial Status

661

clinical trials

Completed411 · 62%
Recruiting84 · 13%
Unknown status55 · 8%
Terminated35 · 5%
Withdrawn25 · 4%
Active, not recruiting25 · 4%
Other26 · 4%

Clinical Trials

Trial Activity

661 trials

Tai Chi for the Prophylaxis of Episodic Migraine: the Efficacy Examination and Mechanism Exploration
Recruiting·TThe Hong Kong Polytechnic University·N/A·NCT05690737·220 enrolled
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
Recruiting·MMedstar Health Research Institute·Phase 4·NCT07301008·60 enrolled
BOTOX® vs. XEOMIN® for Chronic Migraine
Recruiting·—·Phase 3·NCT05598723·128 enrolled
Cabergoline for Episodic Migraine
Recruiting·—·Phase 2·NCT07072910·150 enrolled
Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) of Migraine Patients With Depressive Symptoms Treated With Fremanezumab: A Study to Evaluate Whether Fremanezumab Reduces the Impact on Caregivers and Increases Couple Reciprocity
Recruiting·FFondazione Policlinico Universitario Campus Bio-Medico·N/A·NCT07029126·300 enrolled
Efficacy of Nerve Blocks for Episodic Migraine
Recruiting·MMayo Clinic·Phase 2·NCT05734625·60 enrolled
OnaBotulinumtoxin-A in Chronic Migraine Patients with Short or Long Disease History (the BACH Study)
Recruiting·FFondazione Policlinico Universitario Campus Bio-Medico·N/A·NCT06537700·115 enrolled
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Recruiting·AbbVie logoAbbVie·Phase 3·NCT06810505·420 enrolled
Efficacy of Nerve Block Versus Botox in Chronic Migraine Management
Recruiting·ZZagazig University·N/A·NCT06684249·64 enrolled
Treatment of Tinnitus With Migraine Medications
Recruiting·UUniversity of California, Irvine·Phase 4·NCT04404439·150 enrolled
Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine
Recruiting·IIRCCS National Neurological Institute "C. Mondino" Foundation·N/A·NCT06882122·30 enrolled
Substance P-Induced Migraine Attacks Without Aura
Recruiting·DDanish Headache Center·N/A·NCT06959004·21 enrolled
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
Recruiting·UUniversity of Florence·N/A·NCT06409832·100 enrolled
Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I
Recruiting·HHospital Universitari Vall d'Hebron Research Institute·N/A·NCT06503848·108 enrolled
Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine
Recruiting·—·N/A·NCT06974617·64 enrolled
Page 1 of 45

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)